Treatment of cancers with immunostimulatory HIV tat derivative polypeptides

Abstract

Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, and methods of treating cancer using the Tat derivative polypeptide.

What is claimed is: 
     
       1. A polypeptide having an amino acid sequence comprising, in the following order:
 (i) a transcription factor (TF) domain sequence from a human immunodeficiency virus (HIV) or a simian immunodeficiency virus (SIV) trans-activator of transcription (Tat) protein, wherein the TF domain comprises the amino acid sequence of one of SEQ ID NOs:96-123; 
 (ii) a cysteine-rich domain sequence from SIV, HIV, or a defensin, wherein the cysteine-rich domain comprises the amino acid sequence of one of SEQ ID NOs:124-132; and 
 (iii) a C-terminal domain sequence from a HIV or SIV Tat protein, wherein the C-terminal domain comprises the amino acid sequence of one of SEQ ID NOs:133-150; 
 wherein the TF domain sequence, the cysteine-rich domain sequence, and the C-terminal domain sequence include sequences from at least two different species of primate, and the polypeptide is not SEQ ID NO:2, 3, or 4. 
 
     
     
       2. The polypeptide of  claim 1 , wherein the HIV is HIV-1 or HIV-2. 
     
     
       3. The polypeptide of  claim 1 , wherein the HIV-1 Tat is from a long-term non-progressor. 
     
     
       4. The polypeptide of  claim 1 , wherein the SIV is from a host selected from Table 2. 
     
     
       5. The polypeptide of  claim 1 , wherein the defensin is an α-defensin or a β-defensin. 
     
     
       6. The polypeptide of  claim 1 , further comprising an arginine-rich domain from HIV-1 or HIV-2 Tat. 
     
     
       7. The polypeptide of  claim 1 , wherein at least one of the amino acids in the TF domain is deleted or substituted with an alanine, an aspartic acid, a glutamic acid, a glycine, a lysine, a glutamine, an arginine, a serine, or a threonine. 
     
     
       8. The polypeptide of  claim 7 , wherein the at least one substituted amino acid is a proline. 
     
     
       9. The polypeptide of  claim 1 , wherein the Tat derivative polypeptide has greater than 85% sequence identity to one of SEQ ID NOs 5-95. 
     
     
       10. A pharmaceutical composition comprising a polypeptide according to  claim 1 . 
     
     
       11. A method of treating cancer comprising:
 administering a therapeutically effective amount of a polypeptide of  claim 1 , or the pharmaceutical composition of  claim 10 , to a subject in need thereof; and 
 causing cessation of growth of the cancer or regression of the cancer in the subject. 
 
     
     
       12. The method of  claim 11 , wherein the polypeptide is administered in a plurality of doses. 
     
     
       13. The method of  claim 11 , wherein the administering step comprises a repetitive administration cycle wherein each cycle comprises administering a plurality of doses of the polypeptide in a defined time period followed by a rest period and wherein the cycle is repeated a plurality of times. 
     
     
       14. The method of  claim 11 , wherein the administering step comprises a repetitive administration cycle wherein each cycle comprises administering a plurality of doses of the polypeptide in a defined time period followed by a administration of one or a plurality of doses of a therapeutic agent in a defined time period and wherein the cycle is repeated a plurality of times. 
     
     
       15. The method or use of  claim 14 , wherein the therapeutic agent is cyclophosphamide. 
     
     
       16. A method of inhibiting the suppression of an anti-tumor immune response in a subject with cancer, the method comprising:
 administering a therapeutically effective amount of a polypeptide of  claim 1 , or the pharmaceutical composition of  claim 10 , to the subject; wherein the administration results in reduction or inhibition of growth of the cancer or in regression of the cancer in the subject. 
 
     
     
       17. The method of  claim 16 , wherein at least one pre-treatment tumor from the subject contains at least 5% PD-L1-expressing cells.